• World Neurosurg · Sep 2024

    Cost-Utility Analysis of Deep Brain Stimulation (DBS) for Generalized and Cervical Dystonia: A Perspective from Brazilian Healthcare.

    • Elene Paltrinieri Nardi, Lucas Caetano Araújo Silva, Daniele Yukari Kawakami, Ísis Nalin Fernandes Nonato, Tayanny Margarida Menezes Almeida Biase, Alves FernandesRicardo RibeiroRRInstituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil., and Oliveira de MeloDanielaDNúcleo de Avaliação de Tecnologias em Saúde da Universidade Federal de São Paulo - Diadema (NUD), Diadema, SP, Brazil; Programa de Pós-graduação em Ciências Farmacêuticas da Universidade Federal de São Paulo, Diadema, SP, Brazil. E.
    • Núcleo de Avaliação de Tecnologias em Saúde da Universidade Federal de São Paulo - Diadema (NUD), Diadema, SP, Brazil; Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, SP, Brazil.
    • World Neurosurg. 2024 Sep 5.

    ObjectiveIn the Brazilian public national healthcare system, botulinum toxin type A has traditionally been the sole treatment option for patients with dystonia. However, as of October 2022, Deep Brain Stimulation (DBS) garnered positive recommendations for the condition. This study aims to assess the cost-effectiveness of DBS in treating adults with generalized and cervical dystonia within the Brazilian healthcare context, considering its recent inclusion.MethodsA systematic review identified randomized controlled trials (RCTs) assessing DBS efficacy in treating adults with generalized and cervical dystonia. Two cost-utility analyses compared the cost-effectiveness of DBS plus the Best Clinical Practice (BCP) to BCP alone. Markov models, which included three health states (no clinical improvement, clinical improvement, and death), employed a one-year cycle and a lifetime horizon. The study utilized both one-way and probabilistic sensitivity analyses.ResultsTwo RCTs, one for each condition, revealed superior clinical improvement with DBS when compared to sham simulation. The Incremental Cost-Utility Ratio (ICUR) was $ 1,121.66 for generalized dystonia and $4,556.50 for cervical dystonia. Effectiveness discount rates and age at surgery were identified as influential parameters. In 1,000 Monte Carlo simulations, 99.9% of the ICUR values for generalized dystonia and 74.2 % for cervical dystonia fell below the cost-effectiveness threshold in Brazil ($8,146.64 per QALY).ConclusionsFrom the perspective of the Brazilian public health system, the combination of DBS and BCP appears to be cost-effective for the treatment of both generalized and cervical dystonia when compared to BCP alone.Copyright © 2024. Published by Elsevier Inc.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…